Short Interest in Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Increases By 107.1%

Sol-Gel Technologies Ltd. (NASDAQ:SLGLGet Free Report) saw a large increase in short interest in May. As of May 31st, there was short interest totalling 20,500 shares, an increase of 107.1% from the May 15th total of 9,900 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average daily volume of 32,500 shares, the short-interest ratio is presently 0.6 days.

Sol-Gel Technologies Price Performance

NASDAQ SLGL traded up $0.04 during trading on Friday, reaching $0.88. 78,104 shares of the company’s stock were exchanged, compared to its average volume of 41,415. The business has a 50 day moving average price of $0.81 and a 200-day moving average price of $1.03. The stock has a market capitalization of $24.52 million, a P/E ratio of -1.06 and a beta of 1.53. Sol-Gel Technologies has a fifty-two week low of $0.63 and a fifty-two week high of $4.05.

Sol-Gel Technologies (NASDAQ:SLGLGet Free Report) last issued its earnings results on Monday, May 20th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08). The business had revenue of $0.47 million for the quarter, compared to the consensus estimate of $1.30 million. Sol-Gel Technologies had a negative return on equity of 56.20% and a negative net margin of 1,329.13%. On average, analysts forecast that Sol-Gel Technologies will post -0.83 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright dropped their price target on shares of Sol-Gel Technologies from $9.00 to $6.00 and set a “buy” rating on the stock in a research report on Monday, May 20th.

Check Out Our Latest Stock Report on Sol-Gel Technologies

Sol-Gel Technologies Company Profile

(Get Free Report)

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.

See Also

Receive News & Ratings for Sol-Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol-Gel Technologies and related companies with's FREE daily email newsletter.